摘要
目的探讨维奈克拉联合阿扎胞苷治疗老年急性髓系白血病的效果。方法选取2018年1月至2021年12月宁德市医院血液风湿免疫科收治的96例老年急性髓系白血病患者临床资料,依据治疗方式不同分为对照组和研究组,每组48例。对照组应用阿扎胞苷治疗,研究组应用维奈克拉联合阿扎胞苷治疗。比较两组患者的临床缓解率、不良反应发生率、血小板计数、白细胞计数、心理状态评分[焦虑自评量表(SAS)以及抑郁自评量表(SDS)]。结果研究组患者临床缓解率高于对照组,差异有统计学意义(P<0.05);研究组患者不良反应总发生率低于对照组,差异有统计学意义(P<0.05);研究组患者血小板计数、白细胞计数高于对照组,差异有统计学意义(P<0.05);研究组的SDS、SAS评分低于对照组,差异有统计学意义(P<0.05)。结论老年急性髓系白血病应用维奈克拉联合阿扎胞苷治疗,临床缓解率较好,能够改善不良反应及血液指标,值得应用推广。
Objective To investigate the effect of Venetoclax combined with Azacitidine in the treatment of senile acute myeloid leukemia.Methods Clinical data of 96 elderly patients with acute myeloid leukemia admitted to the Department of Hematology and Rheumatology,Ningde Hospital from January 2018 to December 2021 were selected.According to different treatment methods,they were divided into control group and study group,with 48 cases in each group.The control group was treated with Azacitidine,and the study group was treated with Venetoclax combined with Azacitidine.The clinical remission rate,incidence of adverse reactions,platelet count,white blood cell count,and psychological state scores(self-rating anxiety scale[SAS]and self-rating depression scale[SDS])of the two groups were compared.Results The clinical remission rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in study group was lower than that in control group,and the difference was statistically significant(P<0.05).The platelet count and white blood cell count in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The SDS and SAS scores of the study group were lower than those of the control group,and the differences were statistically significant(P<0.05).Conclusion The treatment of senile acute myeloid leukemia with Venetoclax combined with Azacitidine has a good clinical remission rate and can improve adverse reactions and blood indexes,which is worthy of application and promotion.
作者
陈琦
聂成军
王长贵
许新玉
CHEN Qi;NIE Chengjun;WANG Changgui;XU Xinyu(Department of Hematology and Rheumatology,Ningde Hospital,Fujian Prvince,Ningde352100,China)
出处
《中国当代医药》
CAS
2023年第18期49-52,共4页
China Modern Medicine
